Nuvation Bio, Inc. (NUVB)
|Net Income (ttm)||-64.28M|
|Trading Day||May 7|
|Day's Range||11.02 - 11.60|
|52-Week Range||8.56 - 15.07|
SAN FRANCISCO, CA, April 06, 2021 (GLOBE NEWSWIRE) -- Panacea Acquisition Corp. II (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition,...
Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio
SAN FRANCISCO--(BUSINESS WIRE)--Panacea Acquisition Corp., a Delaware corporation (the “Company”) (NYSE: PANA.U, PANA, PANA WS), announced today that its registration statement on Form S-4 (File No. 333...
Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp. (NYSE: P...
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PAR... [Read more...]
|Stock Exchange |
|Ticker Symbol |
The average 12-month stock price forecast for Nuvation Bio is 17.60, which is an increase of 52.38% from the latest price.